Is there a generic drug market for lorlatinib/lorlatinib?

Since its launch, Lorlatinib has become an important targeted drug for the treatment of ALK-positive non-small cell lung cancer due to its wide coverage of ALK mutation resistance mechanisms and strong ability to penetrate the blood-brain barrier. As global patient demand for highly effective targeted therapies continues to grow, especially in low- and middle-income countries, price has become one of the core issues hindering drug accessibility. Therefore, the generic drug market has gradually begun to pay attention to and deploy non-original versions of lorlatinib.

Although most countries have not yet approved the official marketing of generic drugs of lorlatinib, in some areas with relaxed pharmaceutical production, such as Bangladesh, Laos, Vietnam and other places, some pharmaceutical companies have launched generic versions with the same chemical composition as the original drug. Although these drugs have not entered the strictly regulated markets in Europe and the United States, they already have a certain market share in the drug distribution systems of local or neighboring countries.

Take lorlatinib produced by Luscius Pharmaceuticals in Laos as an example. Its specification is usually 100mg*30 tablets per box. After conversion according to the current exchange rate, the price is about RMB 1,000. This price has obvious cost advantages compared with the cost of original research drugs in European and American markets, which can easily reach tens of thousands of yuan. Bangladeshi pharmaceutical companies such as Incepta and Beacon have also launched products containing Lorlatinib, which are widely used in the international drug purchasing system and meet the treatment needs of some patients with limited economic conditions.

Most of these generic drugs use the same active pharmaceutical ingredients, dosage forms and oral administration methods, and are manufactured with reference to GMP production standards recommended by WHO Some pharmaceutical companies have even obtained quality recognition such as WHO pre-certification and Food and Drug Administration certification. However, most of these generic drugs have not undergone complete Phase III clinical verification, and whether their efficacy is completely consistent with that of the original drugs is still controversial in the academic community. Therefore, when choosing to use it, patients should carefully evaluate the reliability of the drug source and the doctor's recommendations to avoid risks caused by blind use.

Reference materials：https://www.lorbrena.com/